PART 7: THE FALSIFIER
I would rather state the falsifier than defend the thesis.
Nobody has demonstrated that the improved NK-cell function observed after GLP-1 therapy comes from skeletal muscle.
De Barra measured the lymphocytes, not the source. I could not find a human study measuring skeletal-muscle IL-15 production, circulating IL-15 signaling, muscle quality, and NK-cell restoration in the same participants.
The rival explanation is credible.
GLP-1 may act directly on NK cells or through adipose tissue, liver, myeloid cells, the nervous system, or another metabolic intermediary. Reducing lipid toxicity, insulin resistance, leptin signaling, or chronic inflammation may be sufficient.
In that world, muscle is a bystander and I am pattern-matching on a coincidence.
The trans-presentation problem deepens the challenge. If much of IL-15 biology depends on cell-associated IL-15Rα, serum IL-15 may be the wrong readout. A simple model of freely secreted IL-15 traveling from thigh muscle to distant lymphoid tissue becomes less plausible, though mobile immune cells, soluble receptor complexes, or indirect intermediaries remain possible.
The experiment:
1. Measure circulating IL-15, soluble IL-15Rα, and IL-15/IL-15Rα complexes.
2. Biopsy the vastus lateralis for IL-15 and IL-15Rα expression, fiber type, intramuscular fat, mitochondrial function, and inflammatory signaling.
3. Measure NK-cell cytotoxicity, IFN-γ, granzyme B, metabolism, and activating-receptor expression.
4. Compare a fixed low-dose arm with standard titration.
5. Co-culture autologous NK cells with pre- and post-treatment muscle explants using direct-contact and transwell conditions, with and without IL-15 or IL-15Rα blockade.
6. Repeat GLP-1 treatment in an obesity model with inducible skeletal-muscle-specific deletion of Il15 or Il15ra.
If post-treatment muscle activates NK cells only during direct contact — and that effect disappears under IL-15Rα blockade — the trans-presentation model gains support.
If GLP-1 still restores NK function after muscle-specific Il15 or Il15ra deletion, the muscle-derived pathway is not required.
Steps 5 and 6 matter most.
Everything before them is correlation.
A biopsy. Contact-dependent co-culture. Animal genetics.
That this complete chain has not been tested is the most interesting gap in the argument.
The impossible idea is not that skeletal muscle influences immune signaling. That part is established.
The unresolved idea is that GLP-1 therapy repairs the transmitter, restores muscle-derived IL-15 signaling, and reactivates NK-cell cancer surveillance.
That is not a conclusion.
It is a clean, tractable, testable hypothesis.
Somebody go take the biopsy.
English
